Announcements Trials
Browse Landscape

Status

Unknown 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Hodgkin Disease 1

Interventions

Exercise 19Drug Therapy 18pembrolizumab 13Capecitabine 11Blood Specimen Collection 11Surveys and Questionnaires 10Radiotherapy 10Paclitaxel 9Dexamethasone 9Nivolumab 8Standard of Care 7Oxaliplatin 7Fluorouracil 7Erlotinib Hydrochloride 7apatinib 6Interviews as Topic 6Gemcitabine 6Control Groups 6Cisplatin 6Therapeutics 5Neoadjuvant Therapy 5Mindfulness-Based Cognitive Therapy 5Metformin 5Injections 5Everolimus 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5sintilimab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neoplasms × Biological Products × Clear all
NCT04283539 2023-11-13

Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy

National Jewish Health

Unknown
238 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡